E. Ohman J or Asset Management AB Raises Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• E. Ohman J or Asset Management AB increased its stake in Thermo Fisher Scientific by 21.3%, owning 85,675 shares valued at $34.7 million, making it the company's 26th largest position.
• Thermo Fisher announced a quarterly dividend of $0.43 per share, to be paid on October 15th, representing an annualized yield of 0.4%.
• The company reported $5.36 EPS for the last quarter, surpassing analysts' estimates, and has set its fiscal year 2025 EPS guidance between $22.220-$22.840.

E. Ohman J or Asset Management AB boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 21.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 85,675 shares of the medical research company's stock after buying an additional 15,064 shares during the period. Thermo Fisher Scientific accounts for approximately 0.9% of E. Ohman J or Asset Management AB's portfolio, making the stock its 26th largest position. E. Ohman J or Asset Management AB's holdings in Thermo Fisher Scientific were worth $34,738,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Revolve Wealth Partners LLC lifted its holdings in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the period. Monograph Wealth Advisors LLC lifted its holdings in Thermo Fisher Scientific by 0.3% in the fourth quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock worth $4,507,000 after buying an additional 23 shares during the period. Intergy Private Wealth LLC lifted its holdings in Thermo Fisher Scientific by 5.8% in the first quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock worth $208,000 after buying an additional 23 shares during the period. Root Financial Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 5.0% during the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock valued at $252,000 after purchasing an additional 24 shares during the last quarter. Finally, Rossmore Private Capital lifted its holdings in shares of Thermo Fisher Scientific by 0.5% during the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company's stock valued at $2,315,000 after purchasing an additional 24 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company's stock, valued at $56,937,881. The trade was a 0.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $479.48 on Monday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77. The company has a market capitalization of $181.06 billion, a P/E ratio of 27.73, a price-to-earnings-growth ratio of 2.56 and a beta of 0.75. The firm has a 50 day moving average of $466.86 and a 200 day moving average of $450.58.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the previous year, the firm posted $5.37 EPS. The firm's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's payout ratio is 9.95%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a report on Friday, July 11th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Raymond James Financial reiterated an "outperform" rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Seventeen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $592.24.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.